Lisata Therapeutics logo

Lisata TherapeuticsNASDAQ: LSTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 March 1999

Next earnings report:

N/A

Last dividends:

28 October 2013

Next dividends:

N/A
$27.29 M
-61%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-11%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 21:02:31 GMT
$3.28+$0.45(+15.90%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

LSTA Latest News

Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI
proactiveinvestors.com02 November 2024 Sentiment: -

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigating an endometriosis treatment. Dr Buck highlighted Certepetide, Lisata's novel cyclic peptide therapeutic that targets integrins and neuropilin receptors, which are notably elevated in both solid tumors and endometriosis.

Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
zacks.com01 November 2024 Sentiment: POSITIVE

Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
globenewswire.com28 October 2024 Sentiment: POSITIVE

Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab

Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial
proactiveinvestors.com17 September 2024 Sentiment: POSITIVE

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort of its BOLSTER trial. CCA, also known as bile duct cancer, has a five-year survival rate less than 5%, highlighting the urgent need for new and effective treatments.

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
globenewswire.com09 September 2024 Sentiment: POSITIVE

BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in September:

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
globenewswire.com05 September 2024 Sentiment: POSITIVE

BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.

Lisata Therapeutics coming off strong 2Q performance, CEO says
proactiveinvestors.com12 August 2024 Sentiment: POSITIVE

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo told shareholders that the company is coming off a quarter with “strong momentum” to advance clinical studies on its investigational product, certepetide. The biotech firm is looking forward to crucial data readouts from ongoing trials, particularly the Phase 2b ASCEND trial, which could lead to transformative outcomes and potential regulatory approvals.

Lisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMI
proactiveinvestors.com27 July 2024 Sentiment: POSITIVE

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck joined Proactive to discuss the company's new research collaboration with Haystack Oncology which will evaluate the efficacy of its drug candidate certepetide as a therapy for pancreatic cancer. She detailed the collaboration, which will leverage Haystack's minimal residual disease (MRD) technology to detect circulating tumor DNA in blood, which can indicate cancer recurrence or progression.

Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research
proactiveinvestors.com18 July 2024 Sentiment: POSITIVE

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack's MRD technology to evaluate the efficacy of its investigational pancreatic cancer therapy certepetide. Per the research agreement, Lisata will deploy the Haystack MRD technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.

Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
zacks.com16 July 2024 Sentiment: POSITIVE

Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.

  • 1(current)
  • 2

What type of business is Lisata Therapeutics?

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

What sector is Lisata Therapeutics in?

Lisata Therapeutics is in the Healthcare sector

What industry is Lisata Therapeutics in?

Lisata Therapeutics is in the Biotechnology industry

What country is Lisata Therapeutics from?

Lisata Therapeutics is headquartered in United States

When did Lisata Therapeutics go public?

Lisata Therapeutics initial public offering (IPO) was on 01 March 1999

What is Lisata Therapeutics website?

https://www.lisata.com

Is Lisata Therapeutics in the S&P 500?

No, Lisata Therapeutics is not included in the S&P 500 index

Is Lisata Therapeutics in the NASDAQ 100?

No, Lisata Therapeutics is not included in the NASDAQ 100 index

Is Lisata Therapeutics in the Dow Jones?

No, Lisata Therapeutics is not included in the Dow Jones index

When was Lisata Therapeutics the previous earnings report?

No data

When does Lisata Therapeutics earnings report?

Next earnings report date is not announced yet